Even though biomanufacturing experiences ups and downs in demand, it recognizes what is constant—the need to adapt. For example, as the CEO of a leading CDMO quoted in this issue of GEN observes, biotech and biopharma clients appear to be tightening their budgets and pruning their pipelines. And yet long-term trends look promising, especially given the growing importance of therapeutic modalities such as antibody-drug conjugates, oligonucleotides, and cell and gene therapies. In this issue, both near-term challenges and long-term opportunities are discussed in our A-List of Top 10 CDMOs. But what should biomanufacturers do when demand surges? That’s covered in this issue, too, in a feature article about scale-down, scale-up, and scale-out strategies. (There’s also a thought leader article about process intensification.) And, as always, GEN addresses developments of various kinds. Besides offering biomanufacturing coverage, this issue presents articles on gene therapy, digital twins, phage therapy, and biomarker development.